Table 2 Treatment related characteristics
Variable | Breast cancer survivors (n = 30) |
|---|---|
Current Aromatase Inhibitor | 14/30 (47%) |
Current Tamoxifen | 1/30 (3%) |
Past Aromatase Inhibitors | 4/30 (13%) |
Past Tamoxifen | 1/30 (3%) |
Post-menopausal | 28/30 (93%) |
Adriamycin/Epirubicin | 24/30 (80%) |
Herceptin | 8/30 (27%) |
Left chest radiation | 12/30 (40%) |